دورية أكاديمية
PTCy versus CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin Lymphoma:a study of the LWP of the EBMT
| العنوان: | PTCy versus CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin Lymphoma:a study of the LWP of the EBMT |
|---|---|
| المؤلفون: | Montoro, Juan, Ngoya, Maud, Kulagin, Alexander, Giebel, Sebastian, Broers, Annoek E C, Bramanti, Stefania, Halahleh, Khalid, Perez-Simon, Jose Antonio, Solano, Carlos, Ozcelik, Tulay, Blaise, Didier, Sanz, Jaime, Henriques, Marta, Peffault de Latour, Régis, Martino, Rodrigo, Scheid, Christof, Fox, Laura, Gromek, Tomasz, Jurado, Manuel, Sakellari, Ioanna, van Gorkom, Gwendolyn, Matteucci, Paola, Nagler, Arnon, Koc, Yener, Glass, Bertram |
| المصدر: | Montoro , J , Ngoya , M , Kulagin , A , Giebel , S , Broers , A E C , Bramanti , S , Halahleh , K , Perez-Simon , J A , Solano , C , Ozcelik , T , Blaise , D , Sanz , J , Henriques , M , Peffault de Latour , R , Martino , R , Scheid , C , Fox , L , Gromek , T , Jurado , M , Sakellari , I , van Gorkom , G , Matteucci , P , Nagler , A , Koc .... |
| سنة النشر: | 2024 |
| المجموعة: | Maastricht University Research Publications |
| الوصف: | Studies comparing the efficacy of post-transplant cyclophosphamide (PTCy) to conventional calcineurin inhibitor (CNI)-based GVHD prophylaxis regimens in Hodgkin lymphoma (HL) patients are scarce. This study aimed to compare the outcomes of HL patients undergoing hematopoietic stem cell transplantation from HLA-matched donors who received GVHD prophylaxis with either PTCy or conventional CNI-based regimens, using data reported to the EBMT database between January 2015 and December 2022. Among the cohort, 270 recipients received conventional CNI-based prophylaxis and 176 received PTCy prophylaxis. Notably, PTCy prophylaxis was associated with delayed hematopoietic recovery, but also with a lower risk of chronic (25% versus 43%, p<0.001) and extensive chronic GVHD (13% versus 28% p=0.003) compared to the CNI-based cohort. The 2-year cumulative incidence of non-relapse mortality and relapse were 11% versus 17% (p=0.12), and 17% versus 30% (p=0.007) for PTCy and CNI-based, respectively. Moreover, the 2-year overall survival, progression-free survival and GVHD-free, relapse-free survival were all significantly better in the PTCy group compared with the CNI-based group: 85% versus 72% (p=0.005), 72% versus 53% (p<0.001), and 59% versus 31% (p<0.001), respectively. In multivariable analysis, PTCy was associated with a lower risk of chronic and extensive chronic GVHD, reduced relapse, and better OS, PFS, and GRFS compared to the CNI-based platform. Our findings suggest that PTCy as GVHD prophylaxis offers more favorable outcomes compared to conventional CNI-based prophylaxis in adult patients with HL undergoing HSCT from HLA-matched donors. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://cris.maastrichtuniversity.nl/en/publications/af2ee11c-3c40-43d9-8ac1-a7f723b885f8Test |
| DOI: | 10.1182/bloodadvances.2024013328 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2024013328Test https://cris.maastrichtuniversity.nl/en/publications/af2ee11c-3c40-43d9-8ac1-a7f723b885f8Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.E9BBC63A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/bloodadvances.2024013328 |
|---|